Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan
Pediatric Blood & Cancer · 2026
DOI: 10.1002/pbc.32166 ↗At a glance
Klinische Studie (Phase II) in Pediatric Blood & Cancer, 2026. Written by Kenichi Sakamoto and 10 co-authors. Institution: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan. Major MEDLINE topics: Lymphohistiocytosis, Hemophagocytic, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Antineoplastic Combined Chemotherapy Protocols. Cited 1 times so far (Crossref); 31 references. Funded by: Japan Agency for Medical Research and Development, Japan Leukemia Research Fund.
Abstract (original language)
Introduction
Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH) is highly prevalent in Asia. This study evaluated the safety and efficacy of a risk‐stratified treatment guided by dexamethasone (DEX) response and plasma EBV‐DNA levels. Our goal was to optimize etoposide dosing and establish a safer EBV‐HLH treatment.
Methods
We conducted a single‐arm, multicenter, risk‐stratified Phase II clinical trial, EBV‐HLH15, for EBV‐HLH. Patients were classified into three groups based on age, DEX response, and plasma EBV‐DNA load. In the low‐risk (LR) group, etoposide was eliminated from the treatment regimen. In the intermediate‐risk and high‐risk group (IR/HR group), etoposide dosing was reduced by up to 60% compared with the HLH‐2004 study to attenuate treatment intensity, whereas rituximab was added in the HR group to maintain it.
Results
Of 56 patients suspected of EBV‐HLH enrolled, 26 (14 in LR, eight in IR, and four in HR group) were eligible for EBV‐HLH15. The median age was 3.5 years (range: 1.0–8.0). The 1‐year overall survival of the LR and IR/HR groups was 100% and 81.5% (95% confidence interval [CI] = 43.5–95.1), respectively. The event‐free survival of the LR and IR/HR groups was 78.6% (95% CI = 47.2–92.5) and 58.3% (95% CI = 27.0–80.1), respectively. Most events (9/10, mainly deterioration or recurrence of HLH) occurred within 3 weeks of treatment initiation. No patients received rituximab as scheduled in Weeks 5 and 6.
Conclusion
Risk‐stratified treatment for EBV‐HLH guided by DEX response and plasma EBV‐DNA levels after 2 weeks of treatment was safe and effective.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
- HLH/LCH Committee, Japan Children's Cancer Group.
- Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
- Division of Patient Safety, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
- Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
ORCID profiles: Ryu Yanagisawa, Rintaro Ono, Hirokazu Kanegane, Akira Morimoto, Yozo Nakazawa
Funding
- Japan Agency for Medical Research and Development
- Japan Leukemia Research Fund
Cite
APA
Sakamoto, K., Yanagisawa, R., Ono, R., Doi, T., Negishi, T., Kada, A., Saito, A. M., Kanegane, H., Morimoto, A., Shioda, Y., & Nakazawa, Y. (2026). Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32166
Vancouver
Sakamoto K, Yanagisawa R, Ono R, Doi T, Negishi T, Kada A, et al. Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan. Pediatric Blood & Cancer. 2026. doi:10.1002/pbc.32166
BibTeX
@article{Sakamoto2026,
author = {Sakamoto, Kenichi and Yanagisawa, Ryu and Ono, Rintaro and Doi, Takehiko and Negishi, Tatsuya and Kada, Akiko and Saito, Akiko M and Kanegane, Hirokazu and Morimoto, Akira and Shioda, Yoko and Nakazawa, Yozo},
title = {Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/pbc.32166}
}
EUVIMED